Mitotic protein kinase-driven crosstalk of machineries for mitosis and metastasis

Chang-Hyeon Kim, Da-Eun Kim, Dae-Hoon Kim, Ga-Hong Min, Jung-Won Park, Yeo-Bin Kim, Chang K. Sung and Hyungshin Yim

© The Author(s) 2022

Emerging evidence indicates that mitotic protein kinases are involved in metastatic migration as well as tumorigenesis. Protein kinases and cytoskeletal proteins play a role in the efficient release of metastatic cells from a tumor mass in the tumor microenvironment, in addition to playing roles in mitosis. Mitotic protein kinases, including Polo-like kinase 1 (PLK1) and Aurora kinases, have been shown to be involved in metastasis in addition to cell proliferation and tumorigenesis, depending on the phosphorylation status and cellular context. Although the genetic programs underlying mitosis and metastasis are different, the same protein kinases and cytoskeletal proteins can participate in both mitosis and cell migration/invasion, resulting in migratory tumors. Cytoskeletal remodeling supports several cellular events, including cell division, movement, and migration. Thus, understanding the contributions of cytoskeletal proteins to the processes of cell division and metastatic motility is crucial for developing efficient therapeutic tools to treat cancer metastases. Here, we identify mitotic kinases that function in cancer metastasis as well as tumorigenesis. Several mitotic kinases, namely, PLK1, Aurora kinases, Rho-associated protein kinase 1, and integrin-linked kinase, are considered in this review, as an understanding of the shared machineries between mitosis and metastasis could be helpful for developing new strategies to treat cancer.

Knowledge of the cellular machinery involved in cancer tumorigenesis and metastasis is important for developing cancer therapies because the predominant cause of death in cancer patients is metastasis (which accounts for up to 90% of cancer deaths depending on the cancer type). For cell movement and shape alteration, the cytoskeleton must be reorganized both spatially and temporally. Remodeling of the cytoskeleton is involved in several cellular events, including cell division, movement, and migration. Here, we review the role of cytoskeletal proteins in cell division and cell motility. More importantly, we explore which mitotic kinases function in cancer metastasis as well as tumorigenesis. In particular, we focus on PLK1, Aurora kinases, Rho-associated protein kinase 1 (ROCK1), and integrin-linked kinase (ILK) because these mitotic kinases regulate mitotic dynamics and metastasis via posttranslational modification of several substrates, including cytoskeletal proteins, in a manner dependent on extracellular signaling and the tumor microenvironment, as discussed below.

ROLE OF THE CYTOSKELETON IN CELL DIVISION AND METASTATIC MOTILITY

Cell division
Cytoskeletal filaments are important in determining cell shape, dynamic mitotic division, cell movement, intracellular transport, and metastasis. There are three types of cytoskeletal filaments:
microfilaments (e.g., actin), microtubules (e.g., tubulin), and intermediate filaments (e.g., vimentin, desmin, laminin, keratin, and neurofilaments), all of which are involved in cellular events, including cell division and cell movement through polymerization and depolymerization processes\(^{19,22}\) (Fig. 1). In the early stage of mitosis, tubules interact to form a microtubule seed for microtubule nucleation, resulting in growth of microtubules composed of spindle fibers\(^{21,22}\). When spindle fibers appear, chromosomes condense and attach to the microtubules of bipolar spindles and are pulled apart as sister chromatids to opposite poles of the cell\(^{19}\). Bipolar mitotic spindles are organized by centrosomes in the majority of cells, which are the principal microtubule-organizing centers (MTOCs) and regulate microtubule organization and \(\gamma\)-tubulin ring complexes (\(\gamma\)-TuRC). During mitosis, centrosomes nucleate an array of microtubules that are more dynamic than their corresponding interphase counterparts\(^{21,23}\). In addition, the actin cytoskeleton undergoes dramatic alterations and remodeling for cell division, resulting in the typical round shape of mitotic cells. The actin network is involved in centrosome separation and is dependent on cortical actin and myosin. At the cleavage furrow, actin rearranges and forms a contractile ring for cytokinesis (Fig. 2a). Phosphorylation of myosin light chain (MLC) regulates actomyosin contractility, allowing interaction between myosin and actin filaments to produce a mechanical force in cytokinesis\(^{24,25}\) (Fig. 3). The cleavage furrow is primarily regulated by a complex of actin and myosin filaments. The small GTPase Rho localizes at the cleavage furrow as a source of energy, and coordinated exchanges between the active GTP-bound and inactive GDP-bound forms of this protein are crucial for completion of cytokinesis\(^{26,27}\). Ect2, one of the guanine nucleotide-exchange factors that activate Rho family proteins, is required for accumulation and activation of GTP-RhoA in the cleavage furrow during cytokinesis\(^{28}\). Therefore, cytoskeletal molecules such as microtubules, actin, and myosin are central factors that contribute to dynamic morphological alterations and shape changes during mitotic progression.

**Cytoskeleton in cancer metastatic motility and invasion**

The migration and invasion of cancer cells during metastasis are triggered by chemokines and growth factors, including transforming growth factor-\(\beta\) (TGF-\(\beta\)), epidermal growth factor (EGF), and Wnt, and involve the loss of cell–cell adhesion through EMT caused by changes in gene expression and posttranslational modifications\(^{29,30}\). Genetic alterations and posttranslational modification regulate factors involved in cell polarity, cell motility and extracellular matrix degradation during the early stages of metastasis\(^{30,31}\). During metastasis, cytoskeletal machineries regulate cell movement, resulting in the dissemination of cancer cells\(^{19}\). Major molecular factors involved in cell migration are small GTPases, such as Rho, Rac, and Cdc42, which are involved in cytoskeleton remodeling: Arp2/3, which is involved in actin remodeling; and myosin family proteins, which play a role in cell protrusion and contraction\(^{32}\) (Fig. 2b). Migration of cells involves four steps: protrusion (lamellipodia and filopodia), adhesion, contraction, and retraction\(^{11,33}\). In response to EMT-inducing factors such as TGF-\(\beta\) and EGF, the following cellular events occur sequentially, resulting in migration: actin polymerization, protrusion, adhesion linking, actomyosin contraction, disassembly of adhesion at the rear of the cell, and retraction of the trailing cell body\(^{19,33}\). As protrusion is induced by Rac/Cdc42-regulated actin polymerization, polymeric actin filaments (F-actin) are important in mesenchymal cell motility. Adhesion results in stabilization of protrusions. In addition, Rho family GTPases are critical for F-actin and focal adhesion organization\(^{19,33}\). During adhesion, several structural and regulatory proteins are recruited to the complex. Actomyosin, a contractile complex of F-actin and myosin, mediates cell spreading and adhesion to the extracellular matrix\(^{33}\). F-actin lengthens from focal adhesions at the leading edge of cell protrusions, lamellipodia, and filopodia (Fig. 2b). Myosin-driven F-actin merging is assumed to pull on strong focal adhesions at the front during migration and pull on weaker focal adhesions at the rear, moving the cell body forward\(^{11,33}\) (Fig. 2b). These adhesions then have to disassemble as the rear retracts. The

---

**Fig. 1 Three types of cytoskeletal filaments.** a Polymerization and depolymerization of microtubules through GDP/GTP exchange of \(\alpha\)- and \(\beta\)-tubulin heterodimers. b Polymerization and depolymerization of microfilaments through phosphorylation of cofillin. G-actin, monomeric actin form; F-actin, polymeric actin form. c Assembly of intermediate filaments (e.g., vimentin, desmin, laminin, keratin, and neurofilaments) via polymer formation.

---

**Fig. 2 Migration of cells includes several steps: protrusion (lamellipodia and filopodia), adhesion, contraction, and retraction.** Adhesion at the rear of the cell results in the retraction of the trailing cell body.
high tension exerted on the rear adhesions contributes to detachment of the cell. For cells to metastasize, regulation of the cytoskeletal structure is required.

In summary, cytoskeletal proteins change cell shape, are involved in chromosomal segregation, and produce new cells during cell division. In cancer metastasis, they regulate cell movement to other regions and loss of cell–cell adhesion depending on extracellular signaling in the tumor microenvironment.

PLK1 IN TUMOR PROGRESSION AND METASTASIS

Mitotic function of PLK1

PLK1 is a master mitotic kinase in cell division, being involved from centrosomal maturation to mitotic exit. PLK1 expression and activity increase from the G2 phase and peak in mitosis, and their location dramatically transitions from the centrosome and spindle pole to the central spindle, suggesting that several factors interact with PLK1. PLK1 has a catalytic ATP-binding domain at the amino terminus and two substrate-binding polo-box domains at the carboxyl terminus. For mitotic entry, PLK1 binds to and phosphorylates several mitotic substrates, such as cyclin B1 and Cdc25C, resulting in the activation of mitotic CDK1 for mitotic entry (Fig. 3). Phosphorylation of nine-like protein (NLP) induces cells to switch from G2 phase to mitotic phase as a result of NLP release from the centrosome for centrosomal maturation and microtubule nucleation. PLK1 also regulates bipolar spindle formation by phosphorylating BubR1 and PICH.

The microtubule-stabilizing protein translationally controlled tumor protein (TCTP) and the microtubule-destabilizing oncoprotein Op18 are also regulated by PLK1. TCTP is recruited to the mitotic spindle during metaphase by binding microtubules and released at the end of mitosis. For the formation of kinetochore-microtubule attachments, Clip170 is phosphorylated by PLK1 and CK2 at Ser195 and Ser1318, respectively, for the interaction and recruitment of dynactin to the microtubule (+) ends and linkage of microtubules to the cortex through Cdc42 and IQGAP. (Table 1). However, phosphorylation of Op18 by PLK1 at Ser16, Ser25, and Ser39 in Xenopus negatively regulates microtubule stabilization through inactivation of Op18, suggesting that PLK1 promotes microtubule stabilization by inhibiting Op18. In addition, PLK1 regulates the microtubule depolymerase mitotic centromere-associated kinesin (MCAK), a key regulator of mitotic spindle assembly and dynamics, for chromosomal segregation. PLK1-mediated MCAK phosphorylation promotes microtubule depolymerase activity, which is essential for faithful chromosome segregation, in addition to regulating microtubule dynamics and chromosome stability during cell division. HsCYK4 and Ect2 are essential for stimulating RhoA-dependent contractile ring assembly at anaphase onset. PLK1-mediated priming phosphorylation of HsCYK4, a subunit of the centralspindlin complex, functions in targeting Ect2 to the spindle midzone and activating the Ect2-RhoA network to induce formation of the cleavage furrow. During late telophase of mitosis, the intermediate filament vimentin functions in cytokinesis. During mitosis, vimentin is phosphorylated by PLK1 and CDK1 and loses its filament-forming ability. Thus, phosphorylation of mitotic factors by PLK1 is important in the regulation of the cytoskeletal network during mitosis.

Clinical relevance of PLK1 in cancer

Because PLK1 plays a major role in cell division and its transient overexpression induces a transformed phenotype in murine fibroblasts, it has been suggested to function as an oncogene when overexpressed. A recent study revealed that Plk1 overexpression in mouse embryo fibroblasts promoted oncogenic transformation as determined by colony formation in soft agar after 4 weeks. In addition, Plk1 transgenic mice that express Plk1 in a graded manner had a shorter lifespan than wild-type mice due to increased tumor incidence. The expression of PLK1 is high in diverse leukemias and carcinomas, including NSCLC, head and neck, esophageal, pharynx, liver, breast, colon, ovarian, stomach, pancreatic, and prostate cancers, and melanoma. Clinical
studies also revealed that a high level of PLK1 was correlated with low survival of patients with several types of carcinoma, including NSCLC, head and neck cancer, and esophageal cancer. Among 121 NSCLC patients, those with high PLK1 expression had a 5-year survival rate of 24.2%; in contrast, those with moderate expression of PLK1 had a 5-year survival rate of 51.8% ($P = 0.001$), indicating that PLK1 expression is a strong negative prognostic indicator, at least in NSCLC. In a study of 49 esophageal cancer patients, the 3-year survival rate was 54.9% in patients with low PLK1 expression but 24.8% in those with high PLK1 expression ($P < 0.005$). Based on these reports, the PLK1 expression level is a useful prognostic marker in several carcinomas.

In addition, studies of PLK1 expression and tumor stage have revealed that its expression is positively correlated with the clinical stage of NSCLC, colon cancer, prostate cancer, endometrial cancer, breast cancer, and ovarian cancer. In patients with endometrial cancer, the PLK1-stained cell population increased with tumor grade. In ovarian cancer patients, the PLK1-positive cell population increased with cancer stage: 14.74 ± 5.81% in stage 1, 23.00 ± 9.610% in stage 2, and 32.55 ± 9.36% in stage 3, respectively. The PLK1-positive cell population was significantly higher in stage 3 ovarian cancer than in stage 1 ovarian cancer ($P = 0.001$). These studies concluded that PLK1 expression is related to malignancy and has a high risk of cancer metastasis. A meta-analysis of breast cancer patients revealed that high PLK1 expression was correlated with large tumor size (>2 cm) ($P < 0.001$) in 1779 breast cancer patients, higher tumor grade ($P < 0.001$) in 1989 patients and, lymph node metastasis ($P = 0.001$) in 23.00 ± 9.610% in stage 2, and 32.55 ± 9.36% in stage 3, respectively. The PLK1-positive cell population was significantly higher in stage 3 ovarian cancer than in stage 1 ovarian cancer ($P = 0.001$). These studies concluded that PLK1 expression is related to malignancy and has a high risk of cancer metastasis. A meta-analysis of breast cancer patients revealed that high PLK1 expression was correlated with large tumor size (>2 cm) ($P < 0.001$) in 1779 breast cancer patients, higher tumor grade ($P < 0.001$) in 1989 patients and, lymph node metastasis ($P = 0.001$) in 23.00 ± 9.610% in stage 2, and 32.55 ± 9.36% in stage 3, respectively. The PLK1-positive cell population was significantly higher in stage 3 ovarian cancer than in stage 1 ovarian cancer ($P = 0.001$). These studies concluded that PLK1 expression is related to malignancy and has a high risk of cancer metastasis. A meta-analysis of breast cancer patients revealed that high PLK1 expression was correlated with large tumor size (>2 cm) ($P < 0.001$) in 1779 breast cancer patients, higher tumor grade ($P < 0.001$) in 1989 patients and, lymph node metastasis ($P = 0.001$) in 23.00 ± 9.610% in stage 2, and 32.55 ± 9.36% in stage 3, respectively. The PLK1-positive cell population was significantly higher in stage 3 ovarian cancer than in stage 1 ovarian cancer ($P = 0.001$). These studies concluded that PLK1 expression is related to malignancy and has a high risk of cancer metastasis. A meta-analysis of breast cancer patients revealed that high PLK1 expression was correlated with large tumor size (>2 cm) ($P < 0.001$) in 1779 breast cancer patients, higher tumor grade ($P < 0.001$) in 1989 patients and, lymph node metastasis ($P = 0.001$) in 23.00 ± 9.610% in stage 2, and 32.55 ± 9.36% in stage 3, respectively. The PLK1-positive cell population was significantly higher in stage 3 ovarian cancer than in stage 1 ovarian cancer ($P = 0.001$). These studies concluded that PLK1 expression is related to malignancy and has a high risk of cancer metastasis. A meta-analysis of breast cancer patients revealed that high PLK1 expression was correlated with large tumor size (>2 cm) ($P < 0.001$) in 1779 breast cancer patients, higher tumor grade ($P < 0.001$) in 1989 patients and, lymph node metastasis ($P = 0.001$) in 23.00 ± 9.610% in stage 2, and 32.55 ± 9.36% in stage 3, respectively. The PLK1-positive cell population was significantly higher in stage 3 ovarian cancer than in stage 1 ovarian cancer ($P = 0.001$). These studies concluded that PLK1 expression is related to malignancy and has a high risk of cancer metastasis. A meta-analysis of breast cancer patients revealed that high PLK1 expression was correlated with large tumor size (>2 cm) ($P < 0.001$) in 1779 breast cancer patients, higher tumor grade ($P < 0.001$) in 1989 patients and, lymph node metastasis ($P = 0.001$) in 23.00 ± 9.610% in stage 2, and 32.55 ± 9.36% in stage 3, respectively. The PLK1-positive cell population was significantly higher in stage 3 ovarian cancer than in stage 1 ovarian cancer ($P = 0.001$). These studies concluded that PLK1 expression is related to malignancy and has a high risk of cancer metastasis. A meta-analysis of breast cancer patients revealed that high PLK1 expression was correlated with large tumor size (>2 cm) ($P < 0.001$) in 1779 breast cancer patients, higher tumor grade ($P < 0.001$) in 1989 patients and, lymph node metastasis ($P = 0.001$) in 23.00 ± 9.610% in stage 2, and 32.55 ± 9.36% in stage 3, respectively. The PLK1-positive cell population was significantly higher in stage 3 ovarian cancer than in stage 1 ovarian cancer ($P = 0.001$). These studies concluded that PLK1 expression is related to malignancy and has a high risk of cancer metastasis. A meta-analysis of breast cancer patients revealed that high PLK1 expression was correlated with large tumor size (>2 cm) ($P < 0.001$) in 1779 breast cancer patients, higher tumor grade ($P < 0.001$) in 1989 patients and, lymph node metastasis ($P = 0.001$) in 23.00 ± 9.610% in stage 2, and 32.55 ± 9.36% in stage 3, respectively. The PLK1-positive cell population was significantly higher in stage 3 ovarian cancer than in stage 1 ovarian cancer ($P = 0.001$). These studies concluded that PLK1 expression is related to malignancy and has a high risk of cancer metastasis. A meta-analysis of breast cancer patients revealed that high PLK1 expression was correlated with large tumor size (>2 cm) ($P < 0.001$) in 1779 breast cancer patients, higher tumor grade ($P < 0.001$) in 1989 patients and, lymph node metastasis ($P = 0.001$) in 23.00 ± 9.610% in stage 2, and 32.55 ± 9.36% in stage 3, respectively. The PLK1-positive cell population was significantly higher in stage 3 ovarian cancer than in stage 1 ovarian cancer ($P = 0.001$). These studies concluded that PLK1 expression is related to malignancy and has a high risk of cancer metastasis. A meta-analysis of breast cancer patients revealed that high PLK1 expression was correlated with large tumor size (>2 cm) ($P < 0.001$) in 1779 breast cancer patients, higher tumor grade ($P < 0.001$) in 1989 patients and, lymph node metastasis ($P = 0.001$) in 23.00 ± 9.610% in stage 2, and 32.55 ± 9.36% in stage 3, respectively. The PLK1-positive cell population was significantly higher in stage 3 ovarian cancer than in stage 1 ovarian cancer ($P = 0.001$). These studies concluded that PLK1 expression is related to malignancy and has a high risk of cancer metastasis. A meta-analysis of breast cancer patients revealed that high PLK1 expression was correlated with large tumor size (>2 cm) ($P < 0.001$) in 1779 breast cancer patients, higher tumor grade ($P < 0.001$) in 1989 patients and, lymph node metastasis ($P = 0.001$) in 1975 patients, suggesting that PLK1 expression status is closely correlated with important histopathologic characteristics, including the grade and stage of bladder urothelial carcinoma. In addition, PLK1 expression is correlated with the recurrence and metastasis of bladder carcinomas. Therefore, high expression of PLK1 is correlated with clinical outcomes in several cancers, including metastatic cancers.

**PLK1-driven metastasis**

Given that PLK1 expression is elevated in metastases of several cancer types, it is plausible that PLK1 can affect cancer metastasis. PLK1 expression was found to induce EMT in prostate epithelial cells via oncogenic transformation and transcriptional reprogramming. According to that study, inhibition of PLK1 in metastatic prostate cancer cells triggered epithelial characteristics and suppressed cell migration. PLK1-induced phosphorylation of c-Raf at Ser338 and Ser339 was suggested to contribute to c-Raf autophosphorylation of Ser621 as a mechanism of tumorigenesis and metastasis. PLK1-dependent c-Raf phosphorylation induces stimulation of MEK1/2-ERK1/2-Fra1-ZEB1/2 signaling (Fig. 4).

Our recent study demonstrated that PLK1 itself drives cancer metastasis. Since PLK1 expression is a strong negative indicator of prognosis in NSCLC and is higher in metastatic NSCLC, we studied whether active PLK1 drives cancer metastasis. Interestingly, PLK1 phosphorylated at Thr210 (activated PLK1) is abundant in NSCLC during TGF-β-induced EMT. The presence of constitutively active PLK1 induced NSCLC metastasis in a tail-vein injection mouse model, and the specific PLK1 inhibitor volasertib inhibited NSCLC metastasis in this in vivo model. PLK1 with intact ATP-binding and polo-box domains facilitated cell motility and invasion by activating EMT reprogramming and upregulating genes related to the TGF-β-related signaling pathway, amplifying the metastatic properties of NSCLC cells. In addition, PLK1-mediated phosphorylation of the cytoskeletal molecule vimentin at Ser83, Thr327, and Ser339 resulted in the loss of filamentous ability for cell migration. The PI3K/AKT, MAPK, Ras, JAK/STAT, TLR, and TGF-β signaling pathways were found to be
activated in NSCLC cells expressing phosphomimetic vimentin via KEGG pathway analysis of microarray data. Phosphorylated vimentin recruits p-Smad2/3 for nuclear localization, resulting in PD-L1 expression for immune suppression in NSCLC (Fig. 4a). The clinical correlation between the expression of both vimentin and PLK1 and the OS rate of LUAD patients was significant in lung adenocarcinoma. Together, these studies indicate that elevated expression of PLK1 in metastatic NSCLC is correlated with the induction and regulation of metastasis.

**AURORA KINASES IN TUMOR PROGRESSION AND METASTASIS**

**Mitotic function of Aurora A**

As a member of the mitotic serine/threonine Aurora kinase family, Aurora A (also named STK15/BTAK) functions in centrosome maturation, accurate mitotic entry and bipolar spindle assembly. This protein was originally called “Aurora” owing to the monopolar spindles induced by Aurora kinase gene mutation, which are reminiscent of the North pole. This protein has two lobes that align residues of the catalytic cleft. The A loop (residues 274–297) binds to the substrate. For mitotic entry, Cdc25B is phosphorylated on Ser353 at the centrosome before chromatin condensation in late G2 phase, which triggers activation of CDK1 through dephosphorylation by Cdc25B and subsequent relocalization of cyclin B1/CDK1 to the nucleus for mitotic transition. After breakdown of the nuclear envelope, TACC3 phosphorylation by Aurora A is required for centrosomal localization as it promotes microtubule nucleation and stimulates microtubule growth. In addition, CENPA phosphorylation at Ser7 by Aurora A is required for proper microtubule attachment at kinetochores from late prophase to metaphase. Aurora A organizes spindles through regulation of the actin cytoskeleton. Aurora A-mediated phosphorylation of coflin at Ser3 results in actin polymerization, which progresses dynamically from prophase to metaphase. Aurora A located at the spindle pole phosphorylates p150Glued at Ser19 for central spindle assembly and mitotic BRCA1 at Ser308 to ensure proper microtubule plus-end assembly, increasing the rate of microtubule assembly (Fig. 3). Aurora A also regulates the microtubule-binding activity of HURP for mitotic spindle assembly. A unique human microtubule-associated protein (MAP) involved in spindle formation, ASter-associated protein (ASAP), is also regulated by Aurora A through phosphorylation at Ser62. Aurora A is degraded during the metaphase-anaphase transition by APC/C. In summary, Aurora A is essential for mitotic entry and spindle pole assembly through microtubule assembly.

**Clinical relevance of Aurora A in cancer and metastasis**

Overexpression of Aurora A induces chromosome instability and oncogenic transformation. Abnormal overexpression of Aurora A occurs in the early pathological stages of human ovarian tumorigenesis and pancreatic cell transformation. Overexpression of Aurora A and loss of p53 function can accompany centrosome amplification and aneuploidy. Aurora A phosphorylates p53 at Ser215 within the DNA-binding domain to suppress the transactivation activity of p53, suggesting that Aurora A inhibits the transactivation activity of p53 through suppression of DNA binding by direct phosphorylation. In a conditional Aurora A expression system, Aurora A expression and p53 inactivation were required for tumorigenesis, which is supported by clinical observations in hepatocellular carcinoma, indicating that overexpression of Aurora A and inactivation of p53 contribute cooperatively to tumor formation.

Clinically, overexpression of Aurora A is strongly associated with the low survival rates of diverse carcinomas including breast, ovarian, gastric, colorectal, and non-small-cell lung carcinoma. In 151 colorectal adenocarcinoma patients, Aurora A was overexpressed as determined by immunohistochemical analysis of tissue microarrays. Expression of Aurora A was observed in 45% of patients (68/151). Progression-free survival was shorter in patients who expressed high levels of Aurora A than in those who expressed low levels of this protein (P < 0.001). Elevated expression of Aurora A was strongly associated with recurrence in stage 2 or 3 colon cancer, and a high level of Aurora A was associated with poor survival rates in colorectal cancer patients with liver metastasis. In addition, the prognostic significance of AURKA was assessed in breast cancer patients. Increased AURKA expression was strongly associated with poor survival rates (P < 0.05) based on KM-plotter analysis. In ovarian cancer, the Aurora A level was correlated with the OS of patients with stage III ovarian cancer (n = 101) when its expression was stratified as none or marginal (score 0 + 1), low (score 2), or high (score 3). In NSCLC patients, elevated Aurora A expression is associated with poor OS and clinical lymph node metastasis (P = 0.038). In addition, the AURKA level in tumor specimens was found to vary according to the status of differentiation; AURKA was highly expressed in poorly or moderately differentiated (grade 3 or 2) lung cancer specimens compared to well-differentiated cases.

---

**Table 1. Substrates of PLK1 involved in cytoskeletal regulation in mitosis and metastasis.**

| Mitosis | Phosphorylation sites | Mitotic function | Reference |
|---------|-----------------------|------------------|-----------|
| NLP     | Thr22, Ser87, Ser88, Thr161, Ser349, Ser498, Ser670, Ser686 | Centrosomal maturation | 22 |
| BubR1   | Ser676                | Bipolar spindle formation | 36 |
| TCTP    | Ser46, Ser64          | Microtubule dynamics | 41 |
| CLIP170 | Ser195                | Kinetochore-microtubule attachment | 39 |
| Op18    | Ser16, Ser25, Ser39   | Microtubule stabilization | 40 |
| MCAK    | Ser592, Ser595, Ser621, Ser633, Ser715 | Chromosome segregation | 43 |
| HsCYK4  | Ser157                | Chromosome segregation | 38 |
| Vimentin| Ser82                 | Intermediate filament dynamics for cytokinesis | 16 |

| Metastasis | Phosphorylation sites | Metastatic function | Reference |
|------------|-----------------------|---------------------|-----------|
| c-Raf      | Ser338, Ser339        | MEK1/2-ERK1/2-Fra1-ZEB1/2 signal activation | 4 |
| Vimentin   | Ser83, Thr327, Ser339 | Disassembly from filament bundles, Smad translocation, and PD-L1 and Slug expression | 3,15 |
The results of these studies indicate that Aurora A is a crucial factor in tumorigenesis and metastasis.

Aurora A in cancer metastasis

Aurora A has been studied in several cancers including carcinoma of the breast, esophagus, and colorectum and NSCLC. In esophageal cancer, Aurora A overexpression increased esophageal cancer cell invasion and migration owing to induction of matrix metalloproteinases (MMPs) as determined by treatment with an MMP inhibitor, suggesting that Aurora A-induced cell invasiveness is dependent on MMPs. Similarly, in estrogen receptor α-positive breast cancer, overexpression of Aurora A resulted in EMT and a mesenchymal-like phenotype accompanied by high levels of CD44 and HER-2/Neu. Aurora A was significantly elevated in metastatic colorectal cancer, which promoted slug activation and enhanced the metastatic capacity of colorectal cancer cells in vitro and in vivo. The mesenchymal transcription factor Twist1 has been identified as a substrate of Aurora A for EMT in pancreatic cancer. Phosphorylation results in stabilization of Aurora A and promotes EMT. Moreover, Aurora A phosphorylates substrates involved in cell movement such as the GTPaseRalA. Phosphorylation of RalA at Ser194 induces its activation and thus collagen-dependent cell motility and anchorage-independent growth in epithelial cells, although not in cancer cells. This phosphorylation facilitates the association of RalA with RalBP1 for regulation of Cdc42 and Rac1, affecting actin dynamics. In lymphatic metastatic breast cancer, Aurora A also upregulates nonphosphorylated, active cofilin by increasing the phosphatase SSH1 on the basis of immunohistochemistry analysis of 99 breast cancer tissues. Aurora A enriched cofilin and actin reorganization, and Aurora A was shown to regulate cofilin activity by reducing phosphorylation. Inhibition of Aurora A activity using specific shRNAs in a xenograft model suppressed the mesenchymal transition and restored an epithelial phenotype, consequently inhibiting distant metastatic processes, suggesting that Aurora A is important for EMT and metastasis. The loss-of-function experiments described above suggest that inhibition of Aurora A is important in reducing the transition from epithelial to mesenchymal traits.

AURORA B IN TUMOR PROGRESSION AND METASTASIS

Mitotic function of Aurora B

Aurora B functions as a mitotic protein kinase in the late stages of cell division, including processes such as spindle pole formation, chromosomal segregation, and cytokinesis. Aurora B regulates the function of the kinesin-related protein MCAK, a microtubule depolymerase, at microtubule ends by phosphorylating Ser192 during metaphase, resulting in spindle formation and chromosomal movement. ZEN4/MKLP1 is important for central spindle assembly and completion of cytokinesis, which is regulated by Aurora B. For midbody formation and completion of cytokinesis, a TACC1–Aurora B complex forms and functions at the midbody for correct localization of the midzone spindle in late mitosis. For completion of cytokinesis, the GTPase-activating proteins MgcRacGAP and Aurora B associate with each other. Vimentin is phosphorylated by Aurora B at Ser72, contributing to intermediate filament formation at the bridge and to regulation of cleavage furrow formation during the transition from anaphase to cytokinesis. Another intermediate filament, desmin, is disassembled in the cytoplasm after phosphorylation by Aurora B, which induces disassembly of filaments. Aurora B regulates the cleavage furrow and segregation of intermediate filaments coordinately with ROCK1 during cytokinesis. Therefore, Aurora B functions from metaphase to cytokinesis by phosphorylating diverse cytoskeletal proteins and is a crucial mitotic kinase required for proper cell division.

Clinical relevance of Aurora B expression in cancer

Accumulating evidence suggests that aberrant overexpression of Aurora B is associated with carcinogenesis. Increased levels of Aurora B have been observed in carcinomas of the breast.
lung91, stomach92, liver93, ovary94, prostate95, colon96, and thyroid97, as well as osteosarcomas7 and glioblastoma98. The correlation between Aurora B overexpression and poor prognosis (reduced OS and/or disease-free survival rates) has been reported for several cancers, including NSCLC, breast cancer and liver cancer91,93,99. In 312 breast cancer patients, higher levels of Aurora B were significantly correlated with poor survival (P = 0.038), indicating that elevated Aurora B contributes to a poor prognosis in breast cancer90.

In addition to the expression of Aurora B in diverse primary tumors, Aurora B is also expressed at high levels in advanced stages of cancer. In a clinicopathological analysis of 156 ovarian cancer patients, Aurora B expression was significantly higher in poor and moderately differentiated ovarian cancers (53.6% and 28.2% with high expression) than in well-differentiated cancers (10.0% with high expression) (P = 0.02). Another study demonstrated that over half of lymph node metastatic ovarian cancers highly expressed Aurora B (positive vs. negative expression, 50.8% vs. 27.3%) (P = 0.01)94. Aurora B expression was significantly higher in effusions than in primary tumors in advanced stages of ovarian cancer (P = 0.003), suggesting involvement of Aurora B in advanced cancer100. More directly, Aurora B expression was associated with lymph node metastasis in oral squamous cell carcinoma (OSCC). The average level of Aurora B-positive OSCC metastatic lymph nodes was higher than that in primary OSCC9. In addition, elevated expression of Aurora B is associated with early metastatic progression and aggressiveness of breast cancer8. In a breast cancer study, Aurora B expression was compared between normal tissues and cancer tissues using the TCGA database, and cancerous tissues were found to express significantly higher levels of Aurora B than normal tissues (n = 1215, P < 0.001). Therefore, Aurora B expression is correlated with the clinical stage of several tumor types.

**Function of Aurora B in cancer metastasis**

Elevated expression of Aurora B is related to cancer metastasis based on the clinical correlation between its expression and the survival rate of cancer patients. There is evidence that Aurora B induces EMT in breast cancer, which depends on its kinase activity and stabilization of Snail8. Elevated Aurora B activates AKT by phosphorylating Oct4 at Thr343, resulting in activation of AKT and inactivation of GSK3β for stabilization of Snail, consequently
inducing EMT and metastasis in breast cancer cells8 (Fig. 4a). Additionally, Aurora B-mediated phosphorylation of NPM1 at Ser125 accelerated tumor initiation and metastasis to pulmonary nodules in nude mice7. In that model, Aurora B promoted osteosarcoma metastasis through activation of the ERK/NF-kB/ MMP axis as a result of NPM1 phosphorylation7. MCAK is phosphorylated by Aurora B at Ser192, which promotes endothelial cell polarity and directional migration. MCAK regulates directional migration by remodeling microtubules in the cytoskeleton, and phosphorylation plays an important role in this process87 (Fig. 4b). In contrast, depletion of Aurora B using RNA interference suppressed cell invasion and migration in cancers of the breast, stomach, and bone83,92,101. Therefore, upregulated expression and activity of Aurora B contribute to cancer cell invasion, migration, and metastasis in several cancer types, including breast cancer.

ROC1 IN TUMOR PROGRESSION AND METASTASIS

Function of ROC1 in tumor progression

ROCK, a serine/threonine kinase, participates in cell movement by regulating the cytoskeleton102,103. Rho, a small GTPase, is activated by guanine nucleotide exchange factors (GEFs). Upon binding to GTP, RhoA activates ROCK, which regulates a wide range of cellular functions such as actin–myosin contraction, smooth muscle contraction, cell polarity, cell motility, and metastasis through phosphorylation of several substrates depending on the cellular context27,102,104. ROCK1 and ROCK2 share 65% sequence identity and contain an N-terminal kinase domain, a C-terminal pleckstrin homology domain, and cysteine-rich domains104–106. Both are expressed ubiquitously, while their subcellular localization, tissue-specific expression, and functions are different107. Interestingly, no cancer cells that lack both ROCK1 and ROCK2 have been found, indicating that ROCK proteins are essential for tumorigenesis102.

Functionally, ROCK1 activates LIMK1 via phosphorylation at Thr508, resulting in reorganization of the actin cytoskeleton108 (Table 3). During mitosis, LIMK1 regulates actin dynamics by phosphorylating and inactivating coflin, an actin-depolymerizing protein, for accurate spindle orientation108,109. During cytokinesis, the association of Rho-GTP with ROCK1 activates ROCK1, which then phosphorylates several substrates, including vimentin, myosin-binding subunit of myosin phosphatase (MYPT1), and myosin light chain (MLC) (Fig. 3). ROCK1-mediated phosphorylation induces actomyosin contractility, allowing regulation of assembly-disassembly of vimentin at the cleavage furrow or the interaction between myosin II and actin filaments to produce mechanical force in cytokinesis, respectively24,25,110. ROCK1 also indirectly regulates MLC phosphorylation by phosphorylating and inactivating MYPT1102,103. Phosphorylation of the phosphatase MYPT1 at two inhibitory sites, Thr696 and Thr853, inactivates it, resulting in maintenance of MLC phosphorylation111.

Clinical relevance of ROCK1 expression in cancer

Elevation of Rho and ROCK1 expression has been observed in several cancers, including colon carcinoma112, glioblastoma113, hepatocarcinoma114, melanoma9, papillary thyroid carcinoma115, and osteosarcoma116. Kaplan–Meier analysis revealed an inverse relationship between ROCK1 expression and survival in papillary thyroid carcinoma patients115. In addition, high expression of ROCK1 was associated with a more metastatic phenotype in bladder cancer117,118 and papillary thyroid carcinoma115. The RhoA and RhoC proteins and ROCK were more abundant in tumor tissue and metastatic lymph nodes than in normal bladder tissue and uninvolved lymph nodes (P < 0.0001)117. Moreover, elevated expression of ROCK1 was observed in late-stage (T2–T4) and large (≥3 cm) human urothelial bladder tumors compared with early-stage and small tumors, respectively118. These data indicate that ROCK1 is associated with the initiation and progression of bladder cancer. ROCK1 expression was markedly higher in PTC with lymphatic metastasis than in PTC without metastasis. In 225 cases of PTC (128 cases with lymphatic metastasis and 97 cases without lymphatic metastasis), qRT–PCR analysis revealed that ROCK1 expression was significantly higher in tumor tissue than in normal adjacent tissue. Additionally, the expression of ROCK1 was greater in PTC with lymphatic metastasis than in PTC without lymphatic metastasis115. In NSCLC tissues and adjacent normal tissues from 30 patients, ROCK1 expression was significantly higher in NSCLC than in normal tissues (P = 0.0035). ROCK1 expression was also positively correlated with tumor size (P = 0.0038), clinical stage (P = 1.17E-05), and lymph node metastasis in NSCLC (P = 0.0012). Inhibition of ROCK1 using siRNA in NSCLC suppressed cancer cell proliferation and migration through downregulation of cyclin D and cyclin E119. Based on these studies, ROCK1 can be regarded as a marker of a poor prognosis in cancer and a promising target for cancer treatment.

Function of ROCK1 in cancer metastasis

Rho/ROCK signaling is involved in morphological alterations and the metastatic behavior of tumors102,103,112. Recent studies revealed that ROCK1 functions in cancer metastasis through the phosphorylation of several cytoskeletal proteins11,9,117. Briefly, active Rho binds to ROCK1, resulting in activation of MLC and actomyosin contraction. In addition, ROCK1 phosphorylates LIMK1 for metastatic migration as well as mitosis, consequently inhibiting actin depolymerization through coflin-actin-depolymerizing

### Table 3. Substrates of ROCK1 involved in cytoskeletal regulation in mitosis and metastasis.

| Mitosis          | Substrate | Phosphorylation sites | Mitotic function                           | Reference |
|------------------|-----------|-----------------------|--------------------------------------------|-----------|
| LIMK1            | Thr508    | Phosphorylation of coflin at Ser3 and its inactivation, resulting in stabilization of cortical actin networks | 108,109   |
| Vimentin         | Ser71     | Turnover of vimentin at the cleavage furrow | 110       |
| MLC              | Thr18, Ser19 | Actomyosin contraction | 24,25,102 |
| MYPT1            | Thr696, Thr853 | Actomyosin contraction | 111,140   |

| Metastasis       | Substrate | Phosphorylation sites | Metastatic function                           | Reference |
|------------------|-----------|-----------------------|-----------------------------------------------|-----------|
| MLC              | Thr18, Ser19 | Actomyosin contraction | 25,102   |
| LIMK1            | Thr508    | Inhibition of actin depolymerization | 2,108    |
| PTEN             | N.D.      | Activation of P38/PI3K and polymerization of actin filaments for protrusion | 1,2       |
| c-Myc            | Thr58, Ser62 | Transcriptional stabilization and activation of c-Myc for metastatic regulation | 120,121   |

C.-H. Kim et al.
proteins\textsuperscript{108}. Focal adhesion kinase (FAK) is required for mechanosensing and cell motility and regulates focal adhesion dynamics in membrane protrusion\textsuperscript{2}. Recent studies have reported that FAK participates in cell migration and invasion through the PI3K/AKT pathway, which is linked with ROCK1-mediated cell migration and invasion in NSCLC\textsuperscript{1}. ROCK1 knockdown not only suppressed the migration and invasion of lung carcinoma A549 and NCI-H1299 cells but also inhibited the adhesion of NSCLC cells\textsuperscript{3}.

In breast cancer, MCF-7 cells overexpressing ROCK1 metastasized to the hind limbs, liver, and bone\textsuperscript{29}. When mice were treated with siRNA targeting ROCK, all mice remained healthy, indicating that ROCK can induce metastasis. Liu and colleagues hypothesized that ROCK-mediated phosphorylation of c-Myc at Thr58 and/or Ser62 stabilized the transcriptional activity of c-Myc based on their observation that c-Myc expression in metastatic breast cancer cells was significantly increased in vitro and in vivo\textsuperscript{120}. An interaction between ROCK and c-Myc has also been demonstrated in prostate cancer tumorigenesis\textsuperscript{21}. Thus, the interaction between ROCK1 and c-Myc can contribute to tumorigenesis and metastasis. Together, these studies indicate that ROCK1 contributes to metastatic motility and invasion as well as dynamic mitotic events through regulation of cytoskeletal molecules.

**ILK IN TUMOR PROGRESSION AND METASTASIS**

**Mitotic function of ILK**

ILK, a highly conserved serine/threonine kinase, plays an essential role in cell adhesion, cell migration and cell shape changes by interacting with the cytoplasmic domain of β1 and β3 integrins\textsuperscript{122}. Since its identification as a protein that interacts with integrin β1 and β3, ILK has been referred to as an integrin-linked kinase\textsuperscript{122}. ILK is localized at the centrosome and microtubules, forming a complex with tubulin\textsuperscript{123}. ILK helps organize mitotic spindle formation; loss of its activity causes mitotic spindle defects including abnormal mitotic spindle fibers, chromosome abnormalities, and lagging chromatids through disruption of Aurora A/TACC3/ch-TOG interactions\textsuperscript{10,124}. In addition, ILK facilitates the centrosomal localization of RUVBL1 and RUVBL2 via interaction and is involved in tubulin dynamics and mitotic spindle organization\textsuperscript{10,125}. Furthermore, ILK phosphorylates AKT at Ser473 for activation, which affects AKT signaling\textsuperscript{126}. Active AKT phosphorylates and inactivates GSK3β, an interphase regulator of microtubule dynamics at the centrosome, thereby affecting microtubule dynamics in the mitotic spindle\textsuperscript{10,127}. ILK phosphorylates GSK3β on Ser9, which leads to its inactivation, indicating that ILK affects microtubule dynamics in mitosis by reducing the activity of GSK3β in both direct and indirect ways\textsuperscript{127,128}. Therefore, ILK, as a centrosomal protein, regulates mitotic spindle organization for precise mitotic progression.

**Clinical relevance of ILK in cancer**

ILK overexpression in epithelial cells induces tumorigenicity in nude mice, and ILK is recognized as a proto-oncogene\textsuperscript{129}. Overexpression of ILK constitutively upregulated the levels of cyclin D and cyclin A in epithelial cells and consequently induced cell growth\textsuperscript{126}. Suppression of ILK activity with specific inhibitors decreased tumor progression through G2/M phase arrest and apoptosis in glioblastoma cells\textsuperscript{130}. Abnormal expression of ILK has been reported in diverse cancers, and it has been used as a biomarker for cancer diagnosis and prognostication\textsuperscript{129,131,132}. The expression level of ILK and tumor grade were positively correlated in colorectal cancer\textsuperscript{132}, breast cancer\textsuperscript{131}, and NSCLC\textsuperscript{129}. Evaluation of the transcript level of ILK in 64 breast cancer samples and immunohistochemical analysis of normal and cancerous tissues from 163 breast cancer patients revealed that the expression of ILK was significantly greater in cancer tissues than in normal adjacent tissues\textsuperscript{131}. ILK expression was correlated with tumor size, grade, stage, and lymph node metastasis. In addition, the ILK level was highly correlated with OS based on Kaplan–Meier analysis\textsuperscript{131}. Thus, ILK appears to be an important factor affecting the pathogenesis, progression, and prognosis of breast cancer. ILK expression was associated with NSCLC aggressiveness, with a positive correlation between preoperative adjuvant therapy and recurrence in NSCLC cells expressing ILK\textsuperscript{129}. Immunohistochemical analysis of 108 primary tumor tissues derived from NSCLC patients revealed that ILK was highly expressed in 31% of NSCLC tissues, while it was not detected in normal tissues. Expression levels were high in advanced T and N stage cancers\textsuperscript{129}. These data indicate that ILK expression is correlated with the pathogenesis and progression of diverse cancers and that it is a diagnostic and prognostic marker for cancer.

**ILK in metastasis**

Since ILK is a proto-oncogene and regulates cell motility, gain-of-function experiments were performed to determine whether it can drive EMT\textsuperscript{132,133}. Ectopic overexpression of ILK in lung cells promoted cell invasiveness and had a significant impact on EMT, with increased expression of mesenchymal markers\textsuperscript{132,133}. Immunohistochemical analyses of 108 primary tumor tissues derived from lung cancer patients revealed that ILK was highly expressed in 30.6% (33/108) of tumors. ILK expression was positively correlated with lymph node metastasis, indicating that ILK has a causal role in metastasis of lung cancer\textsuperscript{133} and colorectal cancer\textsuperscript{126}. The level of ILK was correlated with tumor grade (P < 0.005), TNM stage (P < 0.001), and invasion depth (P < 0.001), suggesting that it is correlated with tumor progression\textsuperscript{122}. Loss-of-function experiments using siRNA or shRNA targeting ILK have demonstrated that knockdown of ILK represses EMT, tumor growth, and metastasis in tongue and prostate cancers through inactivation of the PI3K/AKT pathway\textsuperscript{134}.

### Table 4. Substrates of ILK involved in cytoskeletal regulation in mitosis and metastasis.

| Mitosis | Phosphorylation sites | Mitotic function | Reference |
|---------|-----------------------|------------------|-----------|
| AKT    | Ser473                | Activation of AKT and inactivation of GSK3β for microtubule dynamics in the mitotic spindle | 10,126,127 |
| GSK3β  | Ser9                  | Inactivation of GSK3β for microtubule dynamics in the mitotic spindle | 10,127,128 |

| Metastasis | Phosphorylation sites | Metastatic function | Reference |
|------------|-----------------------|---------------------|-----------|
| AKT        | Ser473                | Induction of angiogenesis and invasiveness | 141,142   |
| GSK3β      | Ser9                  | Inactivation of GSK3β and stabilization of β-catenin for migration | 128,136   |
| MLC        | Thr18, Ser19          | Cell motility and migration | 137-139   |
ILK has several phosphorylation substrates, such as β-parvin, paxillin, GSK3β, and MLC, that function in the actin cytoskeleton. ILK-mediated phosphorylation of β-parvin allows cells to spread and migrate through the activation of Rac1/Cdc42. ILK phosphorylates GSK3β at Ser9 in breast cancer, affecting the activation of the transcription factor AP1 and the stabilization of β-catenin, which is indirectly related to deregulation of proliferation, migration, and differentiation (Table 4). ILK also directly phosphorylates MLC on Thr18 and Ser19 to promote cell contraction, motility, and migration. ILK functions as an adapter protein through its kinase activity and regulates cell growth, EMT, invasion, migration, and tumor angiogenesis. These data indicate that ILK, through phosphorylation of downstream proteins involved in cell movement and actin organization, is important for cancer metastasis as well as tumor progression.

CONCLUSIONS
Mitosis and metastasis are complex processes requiring dramatic reorganization of cytoskeletal molecules. Several mitotic protein kinases interact with cytoskeletal actin, myosin, and microtubule molecules or related factors directly or indirectly affecting cell shape and migration. Phosphorylation of cytoskeletal filaments regulates cell division, movement, and metastasis. Mounting evidence regarding crosstalk between mitotic protein kinases and metastatic cytoskeletal molecules raises the possibility that mitotic protein kinases function in cell division during cancer metastasis (Tables 1–4). An understanding of the regulation of cellular machineries by mitotic protein kinases in metastasis could provide new strategies for cancer treatment. Importantly, there is clinical evidence that mitotic protein kinases are potential therapeutic targets for suppressing cancer metastasis as well as tumorigenesis. We anticipate that a deeper understanding of the cytoskeletal regulatory mechanisms that function in tumorigenesis by affecting cell division and that play role in cancer metastasis by affecting migration and invasion of cells will provide additional insight into the molecular basis of metastasis and potentially aid in the identification of new therapeutic targets.

REFERENCES
1. Hu, C. et al. ROCK1 promotes migration and invasion of non-small-cell lung cancer cells through the PTEN/PI3K/AKT pathway. Int. J. Oncol. 55, 833–844 (2019).
2. Peng, Y. et al. ROCK isoforms differentially modulate cancer cell motility by mechanosensing the substrate stiffness. Acta Biomater. 88, 86–101 (2019).
3. Rizki, A., Mott, J. D. & Bissell, M. J. Polo-like kinase 1 is involved in invasion and metastasis of squamous cell lung cancer. J. Cell Biol. 171, 431–436 (2005).
4. Bakhoun, S. F. et al. Chromosomal instability drives metastasis through a cysticidal DNA response. Nature 553, 467–472 (2018).
5. Dilek, H., Rogers, M. S. & Straume, O. Are 90% of deaths from cancer caused by metastases? Cancer Med 8, 5574–5576 (2019).
6. Fife, C. M., McCarron, J. A. & Kavallaris, M. Movers and shakers: cell cytoskeleton in cancer metastasis. Br. J. Pharmac. 171, 5507–5523 (2014).
7. Casenghi, M. et al. Polo-like kinase 1 regulates Nlp, a centrosome protein involved in microtubule nucleation. Dev. Cell 5, 113–125 (2003).
8. Hoffmann, I. Centrosomes in mitotic spindle assembly and orientation. Curr. Opin. Struct. Biol. 66, 193–198 (2021).
9. Cheffings, T. H., Burroughs, N. J. & Balasubramanian, M. K. Actomyosin ring formation and tension generation in eukaryotic cytokinesis. Curr. Biol. 26, R719–R737 (2016).
10. Wu, Q. et al. Deficiency in myosin light-chain phosphorylation causes cytokinesis failure and multipolarity in cancer cells. Oncogene 29, 4183–4193 (2010).
11. Koh, S. P., Pham, N. P. & Pieky, A. Seeing is believing: tools to study the role of Ifh GTPases during cytokinesis. Small GTPases https://doi.org/10.1080/21541248.2021.1957384 (2021).
12. Niya, F., Tatsumoto, T., Lee, K. S. & Miki, T. Phosphorylation of the cytokinesis inhibitor Cdc42 at G2/M phase stabilizes association of the mitotic kinase Plk1 and accumulation of GTP-bound RhoA. Oncogene 25, 827–837 (2006).
13. Patel, S. A., Rodrigues, P., Wesolowski, L. & Vanharanta, S. Genomic control of metastasis. Br. J. Cancer 124, 3–12 (2021).
14. Xu, R., Won, J. Y., Kim, C. H., Kim, D. E. & Yim, H. Roles of the phosphorylation of transcriptional factors in epithelial-mesenchymal transition. J. Oncol. 2019, 5810465 (2019).
15. Tam, W. L. & Weinberg, R. A. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat. Med. 19, 1438–1449 (2013).
16. Palmer, T. D., Ashby, W. J., Lewis, J. D. & Zijlstra, A. Targeting tumor cell motility to prevent metastasis. Adv. Drug Deliv. Rev. 63, 568–581 (2011).
17. Ridley, A. J. et al. Cell migration: integrating signals from front to back. Science 302, 1704–1709 (2003).
18. Yim, H. & Eriksen, R. L. Plk1-targeted therapies in TP53- or RAS-mutated cancer. Mutat. Res., Rev. Mutat. Res. 761, 31–39 (2014).
19. Liu, X. S., Song, B. & Liu, X. The substrates of Plk1, beyond the functions in cytokinesis. Protein Cell 1, 999–1010 (2010).
20. Elowee, S., Hummer, S., Uldschmid, A., Li, X. & Nigg, E. A. Tension-sensitive Plk1 phosphorylation on BuβR1 regulates the stability of kinetochore microtubule interactions. Genes Dev. 21, 2205–2219 (2007).
21. Gheghian, L., Loew, D., Lombard, B., Mansfeld, J. & Gavet, O. Plk1 activation in late G2 sets up commitment to mitosis. Cell Rep. 19, 2060–2073 (2017).
22. Burkard, M. E. et al. Plk1 self-organization and priming phosphorylation of HsCrk-α at the spindle midzone regulate the onset of division in human cells. PLoS Biol. 7, e1000111 (2009).
23. Li, H. et al. Phosphorylation of CLIP-170 by Plk1 and CK2 promotes timely formation of kinetochore-microtubule attachments. EMBO J. 29, 2953–2965 (2010).
24. Budde, P. P., Kumagai, A., Dunphy, W. G. & Heald, R. Regulation of Op18 during spindle assembly in Xenopus egg extracts. J. Cell Biol. 153, 149–158 (2001).
25. Yarm, F. R. Phosphorylation regulates the microtubule-stabilizing protein TCTP. Mol. Cell. Biol. 22, 6209–6221 (2002).
26. Fukata, M. et al. Rac1 and Cdc42 capture microtubules through IQGAP1 and CLIP-170. Cell 109, 873–885 (2002).
27. Zhang, L. et al. PLK1 phosphorylates mitotic centromere-associated kinase and promotes its depolymerase activity. J. Biol. Chem. 286, 3033–3046 (2011).
44. Smith, M. R. et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem. Biophys. Res. Commun. 234, 397–405 (1997).

45. Ghegiani, L. et al. PLK1 induces chromosomal instability and overrides cell-cycle checkpoints to drive tumorigenesis. Cancer Res 81, 1293–1307 (2021).

46. Knecht, R. et al. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 59, 2794–2797 (1999).

47. Weichert, W. et al. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 60, 240–245 (2004).

48. Wolf, G. et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 14, 543–549 (1997).

49. Zhang, Y. et al. Augmented expression of polo-like kinase 1 indicates poor clinical outcome for breast patients: a systematic review and meta-analysis. Oncotarget 8, 57723–57722 (2017).

50. Tokumitsu, Y. et al. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int. J. Oncol. 15, 687–692 (1999).

51. Takai, N. et al. Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett. 169, 41–49 (2001).

52. Takai, N. et al. Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett. 164, 41–49 (2001).

53. Zhang, Z., Zhang, G. & Kong, C. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in uterine cervical carcinoma of bladder. Urogynecol Oncol 31, 1222–1230 (2013).

54. Nowakovski, J. et al. Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure 10, 1659–1667 (2002).

55. Glover, D. M., Leibowitz, M. H., McLean, D. A. & Parry, H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 81, 105–105 (1995).

56. Cazales, M. et al. CDC25B phosphorylation by Aurora A occurs at the G2/M transition and is inhibited by DNA damage. Cell cycle 4, 1233–1238 (2005).

57. Dutertre, S. et al. Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2–M transition. J. Cell Sci. 117, 2523–2531 (2004).

58. Kinoishi, K. et al. Aurora A phosphorylation of TACC3/maskin is required for centrosome-dependent microtubule assembly in mitosis. J. Cell Biol. 170, 1047–1055 (2005).

59. Kunitoku, N. et al. CENP-A phosphorylation by Aurora-A in prophase is required for enrichment of Aurora-B at inner centromeres and for kinetochore function. Developmental Cell 5, 853–864 (2003).

60. Ritchey, L. & Chakrabarti, R. Aurora A kinase modulates actin cytoskeleton through phosphorylation of Cofilin: Implication in the mitotic process. Biochem. Biophys. Acta 1843, 2719–2729 (2014).

61. Reboutier, D. et al. Aurora A is involved in central spindle assembly through phosphorylation of Ser19 in P150Glued. J. Cell Biol. 201, 65–79 (2013).

62. Ertcych, N., Stolz, A., Valerius, O., Braus, G. H. & Bastians, H. CHK2-BRCA1 tumor-suppressor axis restrains oncogenic Aurora-A kinase to ensure proper mitotic microtubule assembly. Proc. Natl Acad. Sci. 113, 1817–1822 (2016).

63. Wong, J., Lerrigo, R., Jang, C. Y. & Fang, G. Aurora A regulates the activity of HURP by controlling the accessibility of its microtubule-binding domain. Mol. Biol. Cell 19, 2083–2091 (2008).

64. Wu, J.-C. et al. Identification of V23RAla-Set194 as a critical mediator for Aurora-A-induced cellular motility and transformation by small pool expression screening. J. Biol. Chem. 280, 9013–9022 (2005).

65. Mainmaiti, Y. et al. Aurora kinase A induces papillary thyroid cancer lymph node metastasis by promoting cofilin-1 activity. Biochem. Biophys. Res. Commun. 473, 212–218 (2016).

66. Minoshima, Y. et al. Phosphorylation by aurora B converts MgcRacGAP to a RhoGAP during cytokinesis. Developmental Cell 4, 549–560 (2003).

67. Kawaiji, A. et al. Functional significance of the specific sites phosphorylated in desmin at cleavage furrow: Aurora-A may phosphorylate and regulate type III intermediate filaments during cytokinesis coordinately with Rho-kinase. Mol. Biol. Cell 14, 1489–1500 (2003).

68. Delaval, B. et al. Aurora B-TACC1 protein complex in cytokinesis. Oncogene 23, 4516–4522 (2004).

69. Ritter, A. et al. Functional analysis of phosphorylation of the mitotic centromere-associated kinase by Aurora B kinase in human tumor cells. Cell Cycle 14, 3755–3767 (2015).

70. Guse, A., Mishima, M. & Glotzer, M. Phosphorylation of ZEN-4/MKL1 by aurora B regulates completion of cytokinesis. Curr. Biol. 15, 778–786 (2005).

71. Goto, H. et al. Aurora-B regulates the cleavage furrow-specific vimentin phosphorylation in the cytokinetic process. J. Biol. Chem. 278, 8526–8530 (2003).

72. Zhang, Y. et al. Elevated Aurora B expression contributes to chemoresistance and poor prognosis in breast cancer. Int. J. Clin. Exp. Pathol. 7, 751–757 (2014).

73. Takeshita, M. et al. Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer. Lung Cancer 80, 85–90 (2013).

74. Wang, Z. et al. AURKB promotes the metastasis of gastric cancer, possibly by inducing EMT. Cancer Manag. Res. 12, 6947–6958 (2020).

75. Lin, W. R. et al. The histogenesis of regenerative nodules in human liver cirrhosis. Hepatology 51, 1017–1026 (2010).

76. Chen, Y. J. et al. Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients. Virchows Arch. 455, 431–440 (2009).

77. Chieffi, P. et al. Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate 66, 326–333 (2006).

78. Tatsuoka, M. et al. Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 58, 4811–4816 (1998).

79. Sorrentino, B. et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J. Clin. Endocrinol. Metab. 90, 928–935 (2005).

80. Zeng, W. F., Navaratne, K., Prayson, R. A. & Weil, R. J. Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J. Clin. Pathol. 60, 218–221 (2007).

81. Yu, J., Zhou, J., Xu, F., Bai, W. & Zhang, W. High expression of Aurora-B is correlated with poor prognosis and drug resistance in non-small cell lung cancer. Int. J. Biol. Markers 33, 215–221 (2018).

82. Hetland, T. E. et al. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance. Hum. Pathol. 44, 777–785 (2013).

83. Zhu, L. et al. Knockdown of Aurora-B inhibits osteosarcoma cell invasion and migration via modulating PI3K/Akt/NF-κB signaling pathway. Int. J. Clin. Exp. Pathol. 7, 3984 (2014).

84. Kupper, S. et al. Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis. Elife 5, e12994 (2016).

85. Shi, J. et al. Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment. Cell Death Dis. 4, e493 (2013).
104. Wei, L., Surma, M., Shi, S., Lambert-Cheatham, N. & Shi, J. Novel Insights into the roles of rho kinase in cancer. Arch. Immunol. Ther. Exp. (Warsz) 64, 259–278 (2016).

105. Nakagawa, O. et al. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 392, 189–193 (1996).

106. Wen, W., Liu, W., Yan, J. & Zhang, M. Structure basis and unconventional lipid membrane binding properties of the PH-C1 tandem of rho kinases. J. Biol. Chem. 283, 26263–26273 (2008).

107. Hartmann, S., Ridley, A. J. & Lutz, S. The function of rho-associated kinases ROCK1 and ROCK2 in the pathogenesis of cardiovascular disease. Front. Pharmacol. 6, 276 (2015).

108. Ohashi, K. et al. ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J. Biol. Chem. 275, 3577–3582 (2000).

109. Wu, H. et al. Targeting ROCK1/2 blocks cell division and induces mitotic catastrophe in hepatocellular carcinoma. Biochem. Pharmacol. 184, 114353 (2021).

110. Goto, H. et al. Phosphorylation of vimentin by Rho-associated kinase at a unique amino-terminal site that is specifically phosphorylated during cytokinesis. J. Biol. Chem. 273, 11728–11736 (1998).

111. Khansis, M., Nakatomi, A., Gumpper, K. & Eto, M. Reconstituted human myosin light chain phosphatase reveals distinct roles of two inhibitory phosphorylation sites of the regulatory subunit, MYPT1. Biochemistry 53, 2701–2709 (2014).

112. Croft, D. R. et al. Conditional ROCK activation in vivo induces tumor cell dissemination and angiogenesis. Cancer Res. 64, 8994–9001 (2004).

113. Xu, S. et al. Macrophage migration inhibitory factor enhances autophagy by regulating ROCK1 activity and contributes to the escape of dendritic cell surveillance in glioblastoma. Int. J. Oncol. 49, 2105–2115 (2016).

114. Zhan, Y. et al. MiR-199a/b-5p inhibits hepatocellular carcinoma progression by post-transcriptionally suppressing ROCK1. Oncotarget 8, 67169–67180 (2017).

115. Luo, D. et al. Activation of the ROCK1/MMP-9 pathway is associated with the invasion and poor prognosis in papillary thyroid carcinoma. Int. J. Oncol. 51, 1209–1218 (2017).

116. Wang, Z., Wang, Z., Liu, J. & Yang, H. Long non-coding RNA SNHG5 sponges miR-26a to promote the tumorigenesis of osteosarcoma by targeting ROCK1. Biomed. Pharmacother. 107, 598–605 (2018).

117. Kamali, T. et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin. Cancer Res. 9, 2632–2641 (2003).

118. Mei, Y. et al. Overexpression of ROCK1 promotes cancer cell proliferation and is associated with poor prognosis in human urothelial bladder cancer. Mamm. Genome 32, 466–475 (2021).

119. Xin, T., Lv, W., Liu, D., Jing, Y. & Hu, F. ROCK1 knockdown inhibits non-small-cell lung cancer progression by activating the LAT52/JNK signaling pathway. Aging (Albany NY) 12, 12160–12174 (2020).

120. Liu, S., Goldstein, R. H., Scegansky, E. M. & Rosenblatt, M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 69, 8742–8751 (2009).

121. Zhang, C. et al. ROCK has a crucial role in regulating prostate tumor growth through interaction with p-Myc. Oncogene 33, 5582–5591 (2014).

122. Hannigan, G., Troussard, A. A. & Dedhar, S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK, Not. Rev. Cancer 5, 51–63 (2005).

123. Dobrev, I., Fielding, A., Foster, L. J. & Dedhar, S. Mapping the integrin-linked kinase interactome using SILAC. J. Proteome Res. 7, 1740–1749 (2008).

124. Bettencourt-Dias, M. et al. Genome-wide survey of protein kinases required for kinetochore functions. PLoS Biol. 9, e1001249 (2011).

125. Fielding, A. B. & Dedhar, S. The mitotic functions of integrin-linked kinase. J. Proteome Res. 9, 987 (2010).

126. Delcommene, M. et al. Genome-wide survey of protein kinases required for kinetochore functions. Proc. Natl Acad. Sci. 95, 10730–10735 (1998).

127. Wakefield, J. G., Stephens, D. J. & Tavare, J. M. A role for glycogen synthase kinase-3 in mitotic spindle dynamics and chromosome alignment. J. Cell Sci. 116, 637–646 (2003).

128. Troussard, A. A. et al. Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J. Biol. Chem. 278, 22374–22378 (2003).

129. Takakami, N. Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer 5, 1 (2005).

130. Koul, D. et al. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol. Cancer Ther. 4, 1681–1686 (2005).

131. Tsirtsaki, K. & Gkretsi, V. The focal adhesion protein Integrin-Linked Kinase (ILK) as an important player in breast cancer pathogenesis. Cell. Adh. Migr. 14, 204–213 (2020).

132. Tsuomas, D. et al. ILK expression in colorectal cancer is associated with EMT, cancer stem cell markers and chemotherapy-resistance. Cancer Genomics Proteomics. 15, 127–141 (2018).

133. Okamura, M. et al. Prognostic value of integrin β1-ILK-βAkt signaling pathway in non-small cell lung cancer. Hum. Pathol. 38, 1081–1091 (2007).

134. Zheng, C. C. et al. Significance of integrin-linked kinase (ILK) in tumorigenesis and its potential implication as a biomarker and therapeutic target for human cancer. Am. J. Cancer Res. 9, 186–197 (2019).

135. Filipenko, N. R., Attwell, S., Roskelley, C. & Dedhar, S. Integrin-linked kinase activity regulates Rac- and Cdc42-mediated actin cytoskeleton reorganization via alpha-PLA. Oncogene 24, 5837–5849 (2005).

136. Tan, C. et al. Inhibition of integrin linked kinase (ILK) suppresses β-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC−/− human colon carcinoma cells. Oncogene 20, 133–140 (2001).

137. Deng, J. T., Van Lierop, J. E., Sutherland, C. & Walsh, M. P. Ca. 2+: independent smooth muscle contraction: a novel function for integrin-linked kinase. J. Biol. Chem. 276, 16365–16373 (2001).

138. Deng, J. T., Sutherland, C., Brautigan, D. L., Eto, M. & Walsh, M. P. Phosphorylation of the myosin phosphatase inhibitors, CPI-17 and PHI-1, by integrin-linked kinase. Biochemical J. 367, 517–524 (2002).

139. Shirley, L. A. et al. Integrin-linked kinase affects signaling pathways and migration in thyroid cancer cells and is a potential therapeutic target. Surgery 159, 163–171 (2016).

140. Feng, J. et al. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J. Biol. Chem. 274, 2709–2715 (2001).

141. McDonald, P. C. et al. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res. 68, 1618–1624 (2008).

142. Tan, C. et al. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 5, 79–90 (2004).

ACKNOWLEDGEMENTS

We appreciate the helpful discussions about the manuscript by Hay-Ran Jang (Hanyang University, Korea). This work was supported by a grant to H. Y. from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (NRF-2020R1A2C2008672).

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Hyungshin Yim.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.